• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 T1 加权和 T2 加权磁共振成像评估常染色体显性多囊肾病患者的总肾体积。

T1 vs. T2 weighted magnetic resonance imaging to assess total kidney volume in patients with autosomal dominant polycystic kidney disease.

机构信息

Department of Nephrology, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands.

Department of Radiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

出版信息

Abdom Radiol (NY). 2018 May;43(5):1215-1222. doi: 10.1007/s00261-017-1285-2.

DOI:10.1007/s00261-017-1285-2
PMID:28871393
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5904223/
Abstract

PURPOSE

In ADPKD patients total kidney volume (TKV) measurement using MRI is performed to predict rate of disease progression. Historically T1 weighted images (T1) were used, but the methodology of T2 weighted imaging (T2) has evolved. We compared the performance of both sequences.

METHODS

40 ADPKD patients underwent an abdominal MRI at baseline and follow-up. TKV was measured by manual tracing with Analyze Direct 11.0 software. Three readers established intra- and interreader coefficients of variation (CV). T1 and T2 measured kidney volumes and growth rates were compared with ICC and Bland-Altman analyses.

RESULTS

Participants were 49.7 ± 7.0 years of age, 55.0% female, with estimated GFR of 50.1 ± 11.5 mL/min/1.73 m. CVs were low and comparable for T2 and T1 (intrareader: 0.83% [0.48-1.79] vs. 1.15% [0.34-1.77], P = 0.9, interreader: 2.18% [1.59-2.61] vs. 1.69% [1.07-3.87], P = 0.9). TKV was clinically similar, but statistically significantly different between T2 and T1: 1867 [1172-2721] vs. 1932 [1180-2551] mL, respectively (P = 0.006), with a bias of only 0.8% and high agreement (ICC 0.997). Percentage kidney growth during 2.2 ± 0.3 years was similar for T2 and T1 (9.3 ± 10.6% vs. 7.8 ± 9.9%, P = 0.1, respectively), with a bias of 1.5% and high agreement (ICC 0.843). T2 was more often of sufficient quality for volume measurement (86.7% vs. 71.1%, P < 0.001).

CONCLUSIONS

In patients with ADPKD, measurement of kidney volume and growth rate performs similarly when using T2 compared to T1 weighted images, although T2 performs better on secondary outcome parameters; they are more often of sufficient quality for volume measurement and result in slightly lower intra- and interreader variability.

摘要

目的

在 ADPKD 患者中,使用 MRI 测量总肾体积(TKV)以预测疾病进展速度。传统上使用 T1 加权图像(T1),但 T2 加权成像(T2)的方法已经演变。我们比较了这两种序列的性能。

方法

40 名 ADPKD 患者在基线和随访时接受了腹部 MRI 检查。TKV 通过 Analyze Direct 11.0 软件进行手动追踪测量。三位读者建立了内部和读者间的变异系数(CV)。使用 ICC 和 Bland-Altman 分析比较 T1 和 T2 测量的肾脏体积和增长率。

结果

参与者的年龄为 49.7±7.0 岁,55.0%为女性,估算肾小球滤过率为 50.1±11.5 mL/min/1.73 m。CV 较低且 T2 和 T1 相似(内部读者:0.83%[0.48-1.79]与 1.15%[0.34-1.77],P=0.9,外部读者:2.18%[1.59-2.61]与 1.69%[1.07-3.87],P=0.9)。TKV 在临床上相似,但 T2 和 T1 之间存在统计学上的显著差异:分别为 1867[1172-2721]和 1932[1180-2551]mL(P=0.006),仅存在 0.8%的偏差和高度一致性(ICC 0.997)。在 2.2±0.3 年期间,T2 和 T1 的肾脏生长百分比相似(分别为 9.3±10.6%和 7.8±9.9%,P=0.1),存在 1.5%的偏差和高度一致性(ICC 0.843)。T2 更常用于体积测量(86.7%与 71.1%,P<0.001)。

结论

在 ADPKD 患者中,与 T1 加权图像相比,使用 T2 测量肾脏体积和生长速度的性能相似,尽管 T2 在次要结果参数上表现更好;它们更常用于体积测量,并且导致内部和读者间的变异更小。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0927/5904223/1a285b6fcfb5/261_2017_1285_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0927/5904223/e298dae7a2ae/261_2017_1285_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0927/5904223/92c8783e6132/261_2017_1285_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0927/5904223/1a285b6fcfb5/261_2017_1285_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0927/5904223/e298dae7a2ae/261_2017_1285_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0927/5904223/92c8783e6132/261_2017_1285_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0927/5904223/1a285b6fcfb5/261_2017_1285_Fig3_HTML.jpg

相似文献

1
T1 vs. T2 weighted magnetic resonance imaging to assess total kidney volume in patients with autosomal dominant polycystic kidney disease.基于 T1 加权和 T2 加权磁共振成像评估常染色体显性多囊肾病患者的总肾体积。
Abdom Radiol (NY). 2018 May;43(5):1215-1222. doi: 10.1007/s00261-017-1285-2.
2
Effect of Averaging Measurements From Multiple MRI Pulse Sequences on Kidney Volume Reproducibility in Autosomal Dominant Polycystic Kidney Disease.多 MRI 脉冲序列测量值平均处理对常染色体显性多囊肾病肾脏体积再现性的影响。
J Magn Reson Imaging. 2023 Oct;58(4):1153-1160. doi: 10.1002/jmri.28593. Epub 2023 Jan 16.
3
A rapid high-performance semi-automated tool to measure total kidney volume from MRI in autosomal dominant polycystic kidney disease.一种快速高效的半自动工具,用于从 MRI 测量常染色体显性多囊肾病的总肾体积。
Eur Radiol. 2019 Aug;29(8):4188-4197. doi: 10.1007/s00330-018-5918-9. Epub 2019 Jan 21.
4
Automatic Measurement of Kidney and Liver Volumes from MR Images of Patients Affected by Autosomal Dominant Polycystic Kidney Disease.应用于常染色体显性多囊肾病患者磁共振图像的肾脏和肝脏自动容积测量。
J Am Soc Nephrol. 2019 Aug;30(8):1514-1522. doi: 10.1681/ASN.2018090902. Epub 2019 Jul 3.
5
Automatic total kidney volume measurement on follow-up magnetic resonance images to facilitate monitoring of autosomal dominant polycystic kidney disease progression.在随访磁共振图像上自动测量总肾体积以促进常染色体显性多囊肾病进展的监测。
Nephrol Dial Transplant. 2016 Feb;31(2):241-8. doi: 10.1093/ndt/gfv314. Epub 2015 Aug 31.
6
Total kidney volume in autosomal dominant polycystic kidney disease: intraobserver and interobserver agreement of two methods with MRI.常染色体显性多囊肾病的全肾体积:MRI 两种方法的观察者内和观察者间一致性。
Turk J Med Sci. 2024 Jan 5;54(3):537-544. doi: 10.55730/1300-0144.5820. eCollection 2024.
7
Prognostic Performance of Kidney Volume Measurement for Polycystic Kidney Disease: A Comparative Study of Ellipsoid vs. Manual Segmentation.肾体积测量对多囊肾病预后的预测价值:椭球与手动分割的比较研究。
Sci Rep. 2019 Jul 29;9(1):10996. doi: 10.1038/s41598-019-47206-4.
8
Magnetic Resonance Kidney Parenchyma-T2 as a Novel Imaging Biomarker for Autosomal Dominant Polycystic Kidney Disease.磁共振肾实质 T2 作为常染色体显性多囊肾病的新型成像生物标志物。
Invest Radiol. 2020 Apr;55(4):217-225. doi: 10.1097/RLI.0000000000000633.
9
Reliability of Total Renal Volume Computation in Polycystic Kidney Disease From Magnetic Resonance Imaging.基于磁共振成像的多囊肾病总肾体积计算的可靠性
Acad Radiol. 2015 Nov;22(11):1376-84. doi: 10.1016/j.acra.2015.06.018. Epub 2015 Aug 12.
10
Volume regression of native polycystic kidneys after renal transplantation.肾移植后天然多囊肾的体积缩小
Nephrol Dial Transplant. 2016 Jan;31(1):73-9. doi: 10.1093/ndt/gfv227. Epub 2015 Jun 4.

引用本文的文献

1
The application of radiomics in vestibular schwannomas.放射组学在前庭神经鞘瘤中的应用。
J Laryngol Otol. 2025 Aug;139(8):647-654. doi: 10.1017/S0022215125000258.
2
Kidney phosphate wasting predicts poor outcome in polycystic kidney disease.磷酸盐尿症预示多囊肾病预后不良。
Nephrol Dial Transplant. 2024 Jun 28;39(7):1105-1114. doi: 10.1093/ndt/gfad247.
3
The utility of automatic segmentation of kidney MRI in chronic kidney disease using a 3D convolutional neural network.利用三维卷积神经网络对慢性肾脏病 MRI 进行自动分割的效用。

本文引用的文献

1
Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease.常染色体显性多囊肾病中肿块效应的临床关联
PLoS One. 2015 Dec 7;10(12):e0144526. doi: 10.1371/journal.pone.0144526. eCollection 2015.
2
Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.常染色体显性遗传多囊肾病的影像学分类:一种用于选择临床试验患者的简单模型。
J Am Soc Nephrol. 2015 Jan;26(1):160-72. doi: 10.1681/ASN.2013101138. Epub 2014 Jun 5.
3
Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.
Sci Rep. 2023 Oct 13;13(1):17361. doi: 10.1038/s41598-023-44539-z.
4
Test Retest Reproducibility of Organ Volume Measurements in ADPKD Using 3D Multimodality Deep Learning.使用 3D 多模态深度学习评估 ADPKD 中器官体积测量的测试-重测可重复性。
Acad Radiol. 2024 Mar;31(3):889-899. doi: 10.1016/j.acra.2023.09.009. Epub 2023 Oct 3.
5
Size Matters: How to Characterize ADPKD Severity by Measuring Total Kidney Volume.大小很重要:如何通过测量总肾体积来表征常染色体显性多囊肾病的严重程度。
J Clin Med. 2023 Sep 20;12(18):6068. doi: 10.3390/jcm12186068.
6
Prostaglandin E2, Osmoregulation, and Disease Progression in Autosomal Dominant Polycystic Kidney Disease.前列腺素 E2、渗透压调节和常染色体显性多囊肾病的疾病进展。
Clin J Am Soc Nephrol. 2023 Nov 1;18(11):1426-1434. doi: 10.2215/CJN.0000000000000269. Epub 2023 Aug 14.
7
Clinical Quality Control of MRI Total Kidney Volume Measurements in Autosomal Dominant Polycystic Kidney Disease.常染色体显性多囊肾病中 MRI 全肾体积测量的临床质量控制。
Tomography. 2023 Jul 12;9(4):1341-1355. doi: 10.3390/tomography9040107.
8
Severity of polycystic kidney disease revealed by multiparametric MRI.多囊肾病的严重程度由多参数 MRI 揭示。
Magn Reson Med. 2023 Sep;90(3):1151-1165. doi: 10.1002/mrm.29679. Epub 2023 Apr 24.
9
The association of urinary epidermal growth factors with ADPKD disease severity and progression.尿表皮生长因子与 ADPKD 疾病严重程度和进展的关系。
Nephrol Dial Transplant. 2023 Sep 29;38(10):2266-2275. doi: 10.1093/ndt/gfad050.
10
Automated measurement of total kidney volume from 3D ultrasound images of patients affected by polycystic kidney disease and comparison to MR measurements.从多囊肾病患者的 3D 超声图像自动测量全肾体积,并与 MR 测量结果进行比较。
Abdom Radiol (NY). 2022 Jul;47(7):2408-2419. doi: 10.1007/s00261-022-03521-5. Epub 2022 Apr 27.
DIPAK 1 研究的原理和设计:一项随机对照临床试验,评估兰瑞肽对常染色体显性遗传性多囊肾病疾病进展的疗效。
Am J Kidney Dis. 2014 Mar;63(3):446-55. doi: 10.1053/j.ajkd.2013.10.011. Epub 2013 Dec 15.
4
Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany.常染色体显性遗传多囊肾病的流行病学:德国西南部的深入临床研究。
Nephrol Dial Transplant. 2013 Jun;28(6):1472-87. doi: 10.1093/ndt/gfs551. Epub 2013 Jan 8.
5
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.常染色体显性遗传性多囊肾病的肾脏体积和功能结局。
Clin J Am Soc Nephrol. 2012 Mar;7(3):479-86. doi: 10.2215/CJN.09500911. Epub 2012 Feb 16.
6
Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study.使用抗高血压药物与常染色体显性遗传多囊肾病患者的死亡率:一项基于人群的研究。
Am J Kidney Dis. 2011 Jun;57(6):856-62. doi: 10.1053/j.ajkd.2011.01.023. Epub 2011 Apr 2.
7
Imaging for the prognosis of autosomal dominant polycystic kidney disease.多囊肾病的影像学预后评估。
Nat Rev Nephrol. 2010 Feb;6(2):96-106. doi: 10.1038/nrneph.2009.214.
8
MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement.基于磁共振成像的常染色体显性多囊肾病患者肾脏体积测量:钆增强的可靠性及影响
Clin J Am Soc Nephrol. 2009 Apr;4(4):719-25. doi: 10.2215/CJN.03750708. Epub 2009 Apr 1.
9
Current status of gadolinium toxicity in patients with kidney disease.肾病患者钆毒性的现状
Clin J Am Soc Nephrol. 2009 Feb;4(2):461-9. doi: 10.2215/CJN.06011108.
10
Unified criteria for ultrasonographic diagnosis of ADPKD.常染色体显性多囊肾病超声诊断的统一标准。
J Am Soc Nephrol. 2009 Jan;20(1):205-12. doi: 10.1681/ASN.2008050507. Epub 2008 Oct 22.